Acute Graft Versus Host Disease
36
6
8
9
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
25.0%
9 terminated out of 36 trials
50.0%
-36.5% vs benchmark
17%
6 trials in Phase 3/4
100%
9 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (36)
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
Safety and Clinical Activity of Itolizumab in aGVHD
ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)